EUVIMEDEUVIMED entdecken
Crossref

Divergent Synthesis of (+)-Kuhistanicaol G and (+)-Ferutinin through the Common Intermediate Jaeschkeanadiol

Eric C. Wang, Iljin Shin, Jiyong Hong

Synthesis · 14.08.2026 · 58 (22) · 2629-2638

DOI: 10.1055/a-2927-3974 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Synthesis, erschienen am 14.08.2026. Verfasst von Eric C. Wang und 2 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Motivated by the potent anticancer activity of kuhistanicaol G and ferutinin against the pancreatic cancer cell line PANC-1, we report the total syntheses of (+)-kuhistanicaol G and (+)-ferutinin. Our divergent synthetic strategy proceeds through the common intermediate jaeschkeanadiol and features several key transformations, including tandem radical addition/allylation, chelation-controlled nucleophilic addition, and Chugaev elimination. This work establishes a robust platform for the synthesis of structurally diverse analogues of (+)-kuhistanicaol G and (+)-ferutinin, as well as mechanistic chemical probes, thereby facilitating the future development of natural product-derived therapeutics for pancreatic cancer.

Zitieren

APA

Wang, E. C., Shin, I., & Hong, J. (2026). Divergent Synthesis of (+)-Kuhistanicaol G and (+)-Ferutinin through the Common Intermediate Jaeschkeanadiol. Synthesis, 58(22), 2629-2638. https://doi.org/10.1055/a-2927-3974

Vancouver

Wang EC, Shin I, Hong J. Divergent Synthesis of (+)-Kuhistanicaol G and (+)-Ferutinin through the Common Intermediate Jaeschkeanadiol. Synthesis. 2026;58(22):2629-2638. doi:10.1055/a-2927-3974

BibTeX
@article{Wang2026,
  author = {Wang, Eric C. and Shin, Iljin and Hong, Jiyong},
  title = {Divergent Synthesis of (+)-Kuhistanicaol G and (+)-Ferutinin through the Common Intermediate Jaeschkeanadiol},
  journal = {Synthesis},
  year = {2026},
  volume = {58},
  number = {22},
  pages = {2629--2638},
  doi = {10.1055/a-2927-3974}
}
Kostenlos starten →